BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation, Tax Credit, Expiration Of Research And Development Tax Credits, Percent
Effective Income Tax Rate Reconciliation, Tax Credit, Expiration Of Research And Development Tax Credits, Percent at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:EffectiveIncomeTaxRateReconciliationTaxCreditExpirationOfResearchAndDevelopmentTaxCreditsPercent.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, percent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, percent?
- BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, percent of -1% in Q4 2025.
- What does effective income tax rate reconciliation, tax credit, expiration of research and development tax credits, percent mean?
- Represents the impact of expiring research and development tax credits on the company's effective tax rate. This metric highlights the loss of potential tax savings due to the expiration of credits before they could be utilized. It serves as an indicator of the company's ability to effectively manage and utilize its tax incentive portfolio.